Baird Medical Investment (NASDAQ:BDMD) Stock Rating Upgraded by Wall Street Zen

Baird Medical Investment (NASDAQ:BDMD) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Baird Medical Investment Stock Up 25.3%

BDMD opened at $5.40 on Friday. The company has a fifty day moving average price of $5.12 and a two-hundred day moving average price of $5.09. Baird Medical Investment has a 52 week low of $1.05 and a 52 week high of $12.50.

Institutional Investors Weigh In On Baird Medical Investment

A number of institutional investors have recently made changes to their positions in the stock. Highbridge Capital Management LLC acquired a new position in Baird Medical Investment in the fourth quarter valued at about $855,000. Geode Capital Management LLC bought a new stake in shares of Baird Medical Investment in the 4th quarter valued at about $82,000. Finally, XTX Topco Ltd acquired a new stake in shares of Baird Medical Investment in the 1st quarter valued at approximately $111,000. 19.78% of the stock is owned by institutional investors and hedge funds.

About Baird Medical Investment

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.